Anti-HAI-1 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the aminoterminal end of mature HAI-1 (SPINT1), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Rat, Pan, Monkey, Dog
UniProt
O43278
Size
100ug
Cat. #
RP3HAI1

In stock

SKU
RP-HAI1

Options

As low as: $130.00

Target Overview

Hepatocyte growth factor activator inhibitor type 1 (HAI-1), encoded by the SPINT1 gene (UniProt O43278), is a 529-residue Kunitz-type transmembrane serine protease inhibitor. HAI-1 is a secreted protein that functions as a critical regulator of extracellular proteolytic cascades. It inhibits the serine protease activity of HGFAC (hepatocyte growth factor activator), ST14/matriptase, and TMPRSS13, with inhibition of the latter mediated through its BPTI/Kunitz inhibitor 1 domain. HAI-1 is widely expressed in epithelial tissues and plays essential roles in regulating cellular processes including growth factor activation, epithelial integrity, and protease-dependent signaling. Dysregulation of HAI-1 expression has been implicated in cancer progression, particularly in epithelial malignancies where protease balance governs invasion and metastasis. Researchers study HAI-1 to understand protease inhibitor networks, epithelial homeostasis, and the molecular mechanisms underlying tumor microenvironment remodeling.

Background

HAI-1 belongs to the Kunitz-type protease inhibitor family and serves as a membrane-anchored regulator of serine proteases at epithelial surfaces. Its primary characterized targets include matriptase (ST14), a membrane-type serine protease involved in epithelial differentiation and barrier function, and HGFAC, which activates hepatocyte growth factor (HGF) by proteolytic cleavage. The inhibitory activity of HAI-1 is mediated by its Kunitz domains, which form stable complexes with cognate proteases and prevent substrate access to the active site. HAI-1 undergoes ectodomain shedding, releasing soluble forms that may function as paracrine regulators; this shedding process has been studied as a biomarker in cancer progression. Recent work has examined HAI-1 in the context of urothelial bladder cancer, where tissue expression patterns and ectodomain shedding correlate with clinical outcomes (Saeed AK et al, 2026). Proteomic profiling studies have identified HAI-1 as a candidate biomarker for recurrence and progression risk in non-muscle invasive bladder cancer, highlighting its potential as a prognostic indicator. HAI-1 is also expressed in specialized epithelial structures such as the choroid plexus, where age-related changes in expression may relate to blood-cerebrospinal fluid barrier function. The balance between HAI-1 and its protease targets is increasingly recognized as a determinant of epithelial cancer phenotypes, with implications for invasion, angiogenesis, and immune infiltration. Triple Point Biologics offers three rabbit polyclonal antibodies raised against the aminoterminal region of mature HAI-1, validated for Western blot applications. These reagents enable researchers to detect endogenous HAI-1 in human samples and are predicted to cross-react with mouse, rat, primate, and canine orthologs based on sequence conservation.

References

  1. Saeed AK et al (2026) The role of HAI-1 in urothelial bladder cancer: Tissue expression, ectodomain shedding and clinical outcomes. Biochem Biophys Rep. PubMed · 10.1016/j.bbrep.2026.102600
  2. Murakami R (2026) Morphological and Molecular Characteristics of Choroid Plexus Epithelium in Aged Brains. Int J Mol Sci. PubMed · 10.3390/ijms27052505
  3. Chen CY et al (2026) Membrane-Anchored Serine Protease Inhibitors: Physiological Functions, Mechanisms, and Roles in Cancer. Int J Mol Sci. PubMed · 10.3390/ijms27042000
  4. Silva TA et al (2026) Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Potential Biomarkers for Recurrence and Progression Risk. J Proteome Res. PubMed · 10.1021/acs.jproteome.5c00486

Additional Specifications

Gene Symbol SPINT1
UniProt ID O43278
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Rat, Pan, Monkey, Dog
Pack Size 100ug
Immunogen (aminoterminal end mature HAI-1)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 36-86.
Immunogen (KD1 insert)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 179-261.
Immunogen (Cytoplasmic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 505-529.
Alternate Names HAI-1, Hepatocyte growth factor activator inhibitor type 1, SPINT1, Kunitz-type protease inhibitor 1, Serine protease inhibitor Kunitz-type 1

Frequently Asked Questions

What molecular weight should I expect for HAI-1 on Western blot?

HAI-1 migrates at approximately 58-66 kDa on Western blot, which is higher than the predicted molecular weight of the 529-residue polypeptide due to N-linked glycosylation. You may observe multiple bands representing differentially glycosylated forms or proteolytic fragments. Some cell types also produce a cleaved, secreted form of HAI-1 lacking the transmembrane domain, which migrates slightly faster. Reducing conditions are recommended to disrupt any disulfide-linked complexes with target proteases like matriptase, which can shift the apparent molecular weight upward.

What is the recommended starting dilution for HAI-1 antibody in Western blot?

Start at 1:1000 dilution in blocking buffer containing 5 percent non-fat milk or BSA for overnight incubation at 4°C. This dilution has been validated with whole-cell lysates from epithelial cell lines expressing endogenous HAI-1. If signal is weak in your specific lysate, you can increase concentration to 1:500. Conversely, high-expressing samples may tolerate 1:2000. Always include a positive control lysate from a HAI-1-expressing epithelial cell line such as HaCaT or Caco-2 to confirm antibody performance before troubleshooting.

Does this antibody recognize HAI-1 in mouse and rat samples?

This antibody has validated reactivity against human HAI-1. Cross-reactivity with mouse and rat HAI-1 is predicted based on sequence homology in the immunogen region but has not been experimentally validated by Triple Point Biologics. Human and mouse HAI-1 share approximately 80 percent sequence identity. If you are working with rodent samples, plan to include a positive control from mouse or rat epithelial tissue and be prepared to optimize dilution. Some researchers report successful detection in mouse samples at similar working dilutions to human.

What are good positive and negative control cell lines for HAI-1 expression?

HAI-1 is widely expressed in epithelial cells, so keratinocytes (HaCaT), intestinal epithelial cells (Caco-2, HT-29), and prostate epithelial lines (LNCaP, PC-3) serve as reliable positive controls. Hepatocyte-derived cell lines like HepG2 also express moderate to high levels. For negative controls, consider mesenchymal or hematopoietic cells, though truly HAI-1-null lines are uncommon given its broad epithelial expression pattern. Alternatively, use siRNA knockdown in a positive cell line to confirm antibody specificity and establish the expected band shift on your blot.

Can this antibody detect HAI-1 in immunofluorescence or immunohistochemistry?

Triple Point Biologics antibodies are validated for Western blot and immunohistochemistry. This rabbit polyclonal should perform well in IHC on formalin-fixed paraffin-embedded tissue sections; antigen retrieval with citrate buffer (pH 6.0) is typically effective for HAI-1. For immunofluorescence on cultured cells, start with a 1:100 to 1:200 dilution after fixation with 4 percent paraformaldehyde and permeabilization with 0.1 percent Triton X-100. HAI-1 localizes to the plasma membrane and cytoplasm in epithelial cells, so expect punctate membrane staining with some intracellular signal.

Does HAI-1 form complexes with proteases that affect antibody detection?

Yes. HAI-1 forms tight, SDS-stable complexes with its target serine proteases, particularly matriptase (ST14) and HGFAC. Under non-reducing conditions, you may detect high-molecular-weight bands corresponding to HAI-1-protease complexes in addition to the free HAI-1 monomer. If you are specifically interested in the free inhibitor pool, run samples under reducing conditions with dithiothreitol or beta-mercaptoethanol to disrupt disulfide linkages. Conversely, non-reducing gels can provide insight into the extent of protease inhibition and complex formation in your experimental system.

How should I store the HAI-1 antibody and how long is it stable?

Store the antibody at -20°C in single-use aliquots to avoid repeated freeze-thaw cycles, which can reduce titre and increase background. The antibody is supplied at 100 µg in a glycerol-containing buffer that remains stable for at least 12 months at -20°C. For frequent use, keep a working aliquot at 4°C with 0.02 percent sodium azide; this remains stable for several weeks. Avoid prolonged storage at 4°C without preservative. Do not store diluted antibody in blocking buffer for more than one week, as carrier proteins can degrade and increase non-specific binding.

Why is HAI-1 expression important in epithelial cancer research?

HAI-1 acts as a tumor suppressor in many epithelial cancers by inhibiting matriptase and hepatocyte growth factor activator, proteases that promote invasive growth and metastasis. Loss or downregulation of HAI-1 is associated with increased tumor aggressiveness in gastric, colorectal, ovarian, and prostate cancers. Conversely, maintaining HAI-1 expression preserves epithelial barrier integrity and restrains protease-driven signaling cascades. When designing cancer cell experiments, monitor HAI-1 levels alongside its target proteases to understand the balance of proteolytic regulation. Dysregulated HAI-1 can serve as a prognostic marker in patient-derived samples.

Western blot validation for RP-HAI1 — 3 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

HAI-1: aminoterminal end mature HAI-1 — WB validation
WB · Panel 1 HAI-1: aminoterminal end mature HAI-1
HAI-1: KD1 insert — WB validation
WB · Panel 2 HAI-1: KD1 insert
HAI-1: Cytoplasmic domain — WB validation
WB · Panel 3 HAI-1: Cytoplasmic domain

Custom validation studies available on request — contact us.

Also known as:

  • HAI-1
  • Hepatocyte growth factor activator inhibitor type 1
  • SPINT1
  • Kunitz-type protease inhibitor 1
  • Serine protease inhibitor Kunitz-type 1
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →